Considerations for Bolt Biotherapeutics’ Non- Cytotoxic ADCs

Time: 2:10 pm
day: Track C - Day 2 PM


  • Immune-Stimulating Antibody Conjugates (ISACs) seek to extend the utility of ADCs beyond current applications
  • Discussing Bolt’s ISAC technology, and comparing it to cytotoxic ADC technologies
  • Sharing examples of unique CMC challenges and opportunities for ISACs